To discuss the potential role of continuous subcutaneous insulin infusion (CSII) therapy in patients with insulin-dependent diabetes mellitus (IDDM).
Data Sources:
Published studies describing intensive insulin therapy are reviewed and evaluated.
Data Synthesis:
CSII delivers insulin at a preset basal rate and at bolus doses, when needed, throughout the day. Although this technology allows for greater lifestyle flexibility, the risks of hypoglycemia and ketoacidosis are also increased if the pump malfunctions. Studies have shown that CSII therapy may offer some advantages over conventional insulin therapy; however, the full impact of these benefits has yet to be determined. The National Institutes of Health has recommended seven commercially available insulin pumps for patient use. Cost ranges between $2000 and $3500; the average lifespan is about five years.
Conclusions:
CSII may be a viable alternative to multiple daily injections for maintaining glycemic control in patients with IDDM who require intensive insulin therapy.
Get full access to this article
View all access options for this article.
References
1.
WHO study group. Diabetes mellitus. Technical report, no. 727. Geneva: World Health Organization, 1985.
2.
Physicians guide to insulin-dependent (type I) diabetes: Diagnosis and treatment. Alexandria, VA: American Diabetes Association, 1988.
3.
PickupJCKeenHParsonJAContinuous subcutaneous insulin infusion: An approach to achieving normoglycemia. Br Med J1978; (6107): 204–7.
4.
TamborlaneWVSherwinRSGenetMReduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med1979; 300: 573–8.
EtkindET. How to make pump therapy work. Pract Diabetol1988; 7 (5): 3–5.
7.
The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl J Med1984; 311: 365–72.
8.
The Kroc Collaborative Study Group. Proceedings of a conference on insulin pump therapy in diabetes: Multicenter study of effect on microvascular disease. Diabetes1985; 34 (suppl 3): 1–91.
9.
LauritzenT (The Steno Study Group). Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes1985; 34 (suppl 3): 74–9.
10.
OlsenTDiabetec retinopathy after 3 years' treatment with continuous subcutaneous insulin infusion (CSII). Acta Ophthalmol1987; 65: 185–9.
11.
Dahl-JorgensenKBrinchman-HansenOHanssenKFEffect of near normoglycemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: The Oslo study. Br Med J1986; 293: 1195–9.
12.
Beck-NielsenHEffect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care1985; 8: 585–9.
13.
DCCT Research Group. The diabetes control and complications trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes1986; 35: 530–45.
14.
DCCT Research Group. The diabetes control and complications trial (DCCT): Results of feasibility study. Diabetes Care1987; 10: 1–19.
15.
Dahl-JorgensenKReduction of urinary albumin after 4 years of continuous insulin in insulin-dependent diabetes mellitus. The Oslo study. Acta Endocrinol (Copenh)1988; 117: 19–25.
16.
Dahl-JorgensenKRapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: The Oslo study. Br Med J1985; 290: 811–5.
17.
Dahl-JorgensenKIncrease in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional therapy. Diabetes1987; 36: 1–5.
18.
HelveEA crossover comparison of continuous insulin infusion and conventional injection treatment of type I diabetes. Acta Med Scand1987; 221: 385–93.
19.
HelveEContinuous insulin infusion therapy and retinopathy in patients with type I diabetes. Acta Endocrinol (Copenh)1987; 115: 313–9.
20.
GrimmJJLifestyle, metabolic control, and social implications of pump therapy in 54 routine type I diabetic patients. Diabetes Metab1987; 13: 3–11.
21.
MecklenburgRSAcute complications associated with insulin infusion pump therapy: Report of experience with 161 patients. JAMA1984; 252: 3265–9.
22.
MecklenburgRSGuinnTS. Complications of insulin pumps therapy: The effect of insulin preparation. Diabetes Care1985; 8: 369–70.
23.
Feldt-RasmussenBMathiesenERDeckertT.Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet1983; 2: 1300–4.
24.
FribergTRRosenstockJSanbornGVaghefiARaskinP.The effect of long-term near normal glycemic control on mild diabetic retinopathy. Ophthalmology1985; 92: 1051–8.
25.
GuinnTSBaileyGJMecklenbergRS. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care1988; 11: 46–51.
26.
BellDSHAckersonCCutterGFactors associated with discontinuation of continuous subcutaneous insulin infusion. Am J Sci1988; 295: 23–8.
27.
FeigenbaumE.External open-loop pump for the subcutaneous infusion of insulin in diabetes. Health Technology Assessment Report, 1984, no. 22. Rockville, MD: National Center for Health Services Research and Health Care Technology Assessment.
28.
American Diabetes Association. The cost of continuous subcutaneous insulin infusion (CSII) should be reimbursed by Medicare, 1987.
LoewensteinJE. Insulin pumps and other recent advances in the outpatient treatment of diabetes. Arch Intern Med1988; 144: 755–8.
31.
SaudekCD. Update on insulin pumps. Pract Diabetol1985; 4 (3): l–4.
32.
LevenoKJFortunatoSJRaskinPContinuous subcutaneous insulin infusion during pregnancy. Diabetes Res Clin Pract1988; 4: 257–68.
33.
SkipperE.Diabetes mellitus and pregnancy. A clinical and analytical study with special observations upon thirty-three cases. Q J Med1933; NS2: 353–80.
34.
KarlssonKKjellmerI.The outcome of diabetic pregnancies in relation to the mother's blood sugar level. Am J Obstet Gynecol1972; 112: 213–20.
35.
AdashiEYPintoHTysonJE. Impact of maternal euglycemia on fetal outcome in diabetic pregnancy. Am J Obstet Gynecol1979; 132: 268–74.
36.
CoustanDRBerkowitzRLHobbinsJC. Tight metabolic control of overt diabetes in pregnancy. Am J Med1980; 68: 845–52.
37.
JovanovicLPetersonsOMSarenaBBFeasibility of maintaining normal glucose profiles in insulin dependent pregnant diabetic women. Am J Med1980; 68: 105–12.
38.
IrsiglerKKritzHLovettRG. Controlled drug delivery in the treatment of diabetes mellitus. Crit Rev Ther Drug Carrier Syst1985; 1 (3): 189–280.
39.
FullertonMT. Insulin pumps: A buyer's guide. Diabetes Self-Manage1989; (Jan/Feb): 21–8.
40.
ECRI. Ambulatory insulin infusion pumps. Health Device1987; (17–159): 351–76.
41.
RaskinPRosenstockJ.Blood glucose control and diabetic complications. Ann Intern Med1986; 105: 254–63.
42.
HanssenKFDahl-JorgensenKLauritzenTDiabetic control and microvascular complications: The near-normoglycemic experience. Diabetologia1986; 29: 677–84.
43.
KnightGBoultonAJWardJD. Experience of continuous subcutaneous insulin infusion in the outpatient management of diabetic teenagers. Diabetic Med1986; 3: 82–4.
